Clovis Oncology Inc

+0.07 (+1.21%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)611.70M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$41.13 Million
Adjusted EPS-$0.56
See more estimates
10-Day MA$5.73
50-Day MA$5.77
200-Day MA$5.87
See more pivots

Clovis Oncology Inc Stock, NASDAQ:CLVS

5500 Flatiron Parkway, Suite 100, Boulder, Colorado 80301
United States of America
Phone: +1.303.625.5000
Number of Employees: 429


Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.